Research Facility

Seattle, Washington 98133

2 studies enrolling now · 4 studies all time

What they study most

Advanced Breast Cancer, Carcinoid, Carcinoid Tumor, ER+ Breast Cancer, GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, HER2-negative Breast Cancer, Hepatocellular Carcinoma (HCC), Metastatic Breast Cancer, Neuroendocrine Tumors, Pancreatic NET

Studies at this site

• Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC — Recruiting now
• Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy — Recruiting now
• Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. — Running, not enrolling
• A Comparison of Once a Day Dose Compared to 2 Doses/Day — Completed